IDH2 and acute myeloid leukemia: In parallel, in AML characterized by mutation of the IDH2 gene, preliminary results of a phase I trial of the IDH2 inhibitor AG-221 showed encouraging rates of response, and nice differentiation of treated leukemic cells in vitro and clinically with cases of differentiation syndrome [45].